WO2004015104A1 - 冠動脈形成術後再狭窄のリスク診断方法 - Google Patents
冠動脈形成術後再狭窄のリスク診断方法 Download PDFInfo
- Publication number
- WO2004015104A1 WO2004015104A1 PCT/JP2003/003478 JP0303478W WO2004015104A1 WO 2004015104 A1 WO2004015104 A1 WO 2004015104A1 JP 0303478 W JP0303478 W JP 0303478W WO 2004015104 A1 WO2004015104 A1 WO 2004015104A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- polymorphism
- nucleic acid
- base
- analyzing
- Prior art date
Links
- 208000037803 restenosis Diseases 0.000 title claims abstract description 150
- 238000000034 method Methods 0.000 title claims abstract description 107
- 238000007887 coronary angioplasty Methods 0.000 title claims abstract description 81
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 650
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 648
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 648
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 159
- 230000002068 genetic effect Effects 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 252
- 239000002773 nucleotide Substances 0.000 claims description 107
- 125000003729 nucleotide group Chemical group 0.000 claims description 107
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 67
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 55
- 102000003886 Glycoproteins Human genes 0.000 claims description 44
- 108090000288 Glycoproteins Proteins 0.000 claims description 44
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 40
- 238000001514 detection method Methods 0.000 claims description 35
- 108010024212 E-Selectin Proteins 0.000 claims description 32
- 108090001067 Angiotensinogen Proteins 0.000 claims description 26
- 108091006027 G proteins Proteins 0.000 claims description 24
- 102000030782 GTP binding Human genes 0.000 claims description 24
- 108091000058 GTP-Binding Proteins 0.000 claims description 24
- 108010024976 Asparaginase Proteins 0.000 claims description 22
- 101150078994 La gene Proteins 0.000 claims description 22
- 108050008832 Fatty acid-binding protein, intestinal Proteins 0.000 claims description 19
- 101150033839 4 gene Proteins 0.000 claims description 18
- 108010008184 Aryldialkylphosphatase Proteins 0.000 claims description 18
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 17
- 108010071619 Apolipoproteins Proteins 0.000 claims description 16
- 102000007592 Apolipoproteins Human genes 0.000 claims description 15
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 13
- 108010076807 Apolipoprotein C-I Proteins 0.000 claims description 12
- 102000011772 Apolipoprotein C-I Human genes 0.000 claims description 12
- 101150062179 II gene Proteins 0.000 claims description 12
- 108010079274 Thrombomodulin Proteins 0.000 claims description 12
- 101150013191 E gene Proteins 0.000 claims description 10
- 101150017040 I gene Proteins 0.000 claims description 10
- 108010038179 G-protein beta3 subunit Proteins 0.000 claims description 9
- 241001250090 Capra ibex Species 0.000 claims description 8
- 108010077971 Plasminogen Inactivators Proteins 0.000 claims description 7
- 101150084750 1 gene Proteins 0.000 claims description 6
- 108010024284 Apolipoprotein C-II Proteins 0.000 claims description 6
- 108010041111 Thrombopoietin Proteins 0.000 claims description 6
- 102100039998 Apolipoprotein C-II Human genes 0.000 claims description 5
- 102000010752 Plasminogen Inactivators Human genes 0.000 claims description 5
- 239000002797 plasminogen activator inhibitor Substances 0.000 claims description 5
- 101710083182 Fatty acid-binding protein 1 Proteins 0.000 claims description 4
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 claims description 4
- 101710189565 Fatty acid-binding protein, liver-type Proteins 0.000 claims description 4
- 102000004881 Angiotensinogen Human genes 0.000 claims description 3
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 abstract description 17
- 230000037431 insertion Effects 0.000 abstract description 17
- 101150096316 5 gene Proteins 0.000 abstract 1
- 101150039504 6 gene Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 154
- 239000000523 sample Substances 0.000 description 101
- 230000000692 anti-sense effect Effects 0.000 description 89
- 238000004458 analytical method Methods 0.000 description 68
- 238000002372 labelling Methods 0.000 description 51
- 230000000295 complement effect Effects 0.000 description 47
- 239000000126 substance Substances 0.000 description 46
- 230000003902 lesion Effects 0.000 description 32
- 108091081021 Sense strand Proteins 0.000 description 29
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 28
- 238000003745 diagnosis Methods 0.000 description 19
- 102000013918 Apolipoproteins E Human genes 0.000 description 13
- 108010025628 Apolipoproteins E Proteins 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 238000012098 association analyses Methods 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 108700028369 Alleles Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 102100023471 E-selectin Human genes 0.000 description 10
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 10
- 210000004351 coronary vessel Anatomy 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 8
- 238000007477 logistic regression Methods 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 230000000391 smoking effect Effects 0.000 description 8
- 102100026748 Fatty acid-binding protein, intestinal Human genes 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 102100029470 Apolipoprotein E Human genes 0.000 description 6
- 101000911337 Homo sapiens Fatty acid-binding protein, intestinal Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000010187 selection method Methods 0.000 description 6
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 6
- 108010060815 thrombospondin 4 Proteins 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 102000030169 Apolipoprotein C-III Human genes 0.000 description 5
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 5
- 101100208245 Danio rerio thbs4b gene Proteins 0.000 description 5
- 101150053966 THBS4 gene Proteins 0.000 description 5
- 102100029219 Thrombospondin-4 Human genes 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000002316 cosmetic surgery Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- 101150110633 112 gene Proteins 0.000 description 4
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 101000690100 Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 101100029173 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) SNP2 gene Proteins 0.000 description 4
- 108010003541 Platelet Activating Factor Proteins 0.000 description 4
- 101100094821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SMX2 gene Proteins 0.000 description 4
- 102100024121 U1 small nuclear ribonucleoprotein 70 kDa Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 108010064733 Angiotensins Proteins 0.000 description 3
- 201000000057 Coronary Stenosis Diseases 0.000 description 3
- 101150067056 Epsilon gene Proteins 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 3
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000010339 dilation Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 238000002608 intravascular ultrasound Methods 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000010577 post-coronary angioplasty Methods 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101710126783 Acetyl-hydrolase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010048623 Collagen Receptors Proteins 0.000 description 2
- 206010011089 Coronary artery stenosis Diseases 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100036250 GPI mannosyltransferase 4 Human genes 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- 101001074618 Homo sapiens GPI mannosyltransferase 4 Proteins 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000000507 Integrin alpha2 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 108010045766 Platelet Glycoprotein GPIb-IX Complex Proteins 0.000 description 2
- 101100236128 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LSM2 gene Proteins 0.000 description 2
- 108090000184 Selectins Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 208000035868 Vascular inflammations Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2h-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000272470 Circus Species 0.000 description 1
- 101710130857 Class E basic helix-loop-helix protein 22 Proteins 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710200331 Cytochrome b-245 chaperone 1 Proteins 0.000 description 1
- 102100037186 Cytochrome b-245 chaperone 1 Human genes 0.000 description 1
- 101710119396 Cytochrome b-245 chaperone 1 homolog Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000632511 Daviesia arborea Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000015689 E-Selectin Human genes 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241001505295 Eros Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 102000023159 Platelet Glycoprotein GPIb-IX Complex Human genes 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 101150077745 ex gene Proteins 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000053020 human ApoE Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphate Chemical class 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 101150012509 sub gene Proteins 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to a detection method using a gene associated with restenosis after coronary angioplasty. More specifically, the present invention relates to a detection method using polymorphisms of a plurality of genes related to restenosis after coronary angioplasty, and a kit used in the method. The present invention can be used as a risk diagnosis of restenosis after coronary angioplasty. Background art
- Restenos is af ter coronary angioplasty: a mul t ivariate statistical mode I to relative rate ion and procedure variabl es to restenos is.
- the M- HEART Invest igators. "Am Col I Cardiol 1991; 18: 647-56 .; Weintraub WS, Kos inski AS, Brown CL 3rd, King SB 3rd.Can restenos is af ter coronary angioplasty be predicted from cl inical variables? J Am Co II Cardiol 1993; 21: 6-14 .; Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes me II it us on early and late outcome after percutaneous transluminal coronary angioplasty.
- Circulation 1996; 94: 35-43, reported that neointimal thickening was the most important mechanism in in-stent restenosis (Hoffmann R, Mintz GS, Dussa i A ant GR, et a I. Patterns and mechanisms of in-stent restenosis.A serial intravascular ultrasound study.Circulation 1996; 94: 1247-5 5.
- One method to prevent restenosis after coronary angioplasty is To identify restenosis susceptibility genes Angiotensin converting enzymes (Amant C, Bauters C, Bodar t J-C, et a D alele of the angiotensin converting enzyme is a major risk factor for restenosis after cor onary stenting.
- the angiotensinogen gene 235T variant is associated wi th an increased risk of restenosis after percutaneous transluminal coronary angioplasty.Cl in Sci 2000; 99: 19-25.), Apolipotan No ⁇ 0 ⁇ E (van Bockxmeer FM, Mamo t te CDS, Gibbons FR, Taylor RR. Apo I i poprote in ⁇ 4 homozygos i ty-a determinant of restenos is af ter coronary angioplasty. ), Platelet glycoprotein I lia (Walter DH, Schachinger V, Eisner M, Dimme Ier S, Zei her AM.
- the present invention has been made in view of the above background, and an object of the present invention is to provide means for diagnosing a genetic risk of restenosis after coronary angioplasty with high accuracy and high predictive accuracy.
- the present inventors have estimated the association with coronary atherosclerosis, coronary artery »constriction, hypertension, diabetes, hyperlipidemia, etc. using several public databases to achieve the above object.
- a method for detecting a genotype of a nucleic acid sample comprising the following step (a):
- a method for detecting a genotype of a nucleic acid sample comprising the following step (b):
- a method for detecting a genotype of a nucleic acid sample comprising the following step (d):
- a method for diagnosing the risk of restenosis after coronary angioplasty comprising the following steps (i) to (iii):
- a method for diagnosing risk of restenosis after coronary angioplasty comprising the following steps (iv) to (vi):
- a method for diagnosing risk of restenosis after coronary angioplasty comprising the following steps (V i i) to (i X):
- (V i i) a step of analyzing two or more polymorphisms selected from the group consisting of the following (12) to (17) in the nucleic acid sample;
- a method for diagnosing risk of restenosis after coronary angioplasty comprising the following steps (x) to (xii):
- a genotype detection kit comprising two or more nucleic acids selected from the group consisting of the following (1) to (6):
- nucleic acid for analyzing the polymorphism at nucleotide position 3932 of the apolipoprotein E gene
- nucleic acid for analyzing a polymorphism at base number -482 of apolipoprotein C-1 I I gene (5) nucleic acid for analyzing a polymorphism at base number -482 of apolipoprotein C-1 I I gene
- a genotype detection kit comprising two or more nucleic acids selected from the group consisting of the following (7) to (11):
- a genotype detection kit comprising two or more nucleic acids selected from the group consisting of the following (12) to (17):
- (21) Dali a nucleic acid for analyzing a polymorphism at base number 1018 of the coprotein Iba gene
- (22) a nucleic acid for analyzing a polymorphism at nucleotide position 3932 of the apolipoprotein E gene;
- An immobilized nucleic acid comprising two or more nucleic acids selected from the group consisting of the following (1) to (7) fixed to an insoluble support,
- nucleic acid for analyzing the polymorphism at nucleotide position 3932 of the apolipoprotein E gene
- G-protein a nucleic acid for analyzing the polymorphism at position 825 of the 83-subunit gene
- nucleic acid for analyzing the polymorphism at nucleotide position 1186 of the thrompospondin 4 gene
- nucleic acid for analyzing the polymorphism at nucleotide number-863 of the tumor necrosis factor ⁇ gene
- (21) a nucleic acid for analyzing a polymorphism at base number 1018 of the daricoprotein lba gene
- FIG. 1 is a table summarizing the 112 gene polymorphisms examined in the screening association analysis in Examples.
- FIG. 2 is a table summarizing 112 gene polymorphisms examined in the screening association analysis in the same example.
- FIG. 3 shows the primers (SEQ ID NOS: 31, 32, 33, 28, 29, 30, 16, 16, 17 and 18) used in order to determine the genotype in the examples. , 46, 47, 48, 49, 50, 51, 25, 26, 27, 19, 20, 20, 21, 5, 2, 5, 3, 5, 4, 5, 7 8, 59, 55, 56), probes (SEQ ID NOs: 60, 61, 62, 63, 64, 65, 66, 67) in order from the top and other conditions It is a table.
- FITC stands for full-year-old restained isothiocyanate
- TxR stands for Texas red
- Biotin stands for big-tin.
- FIG. 4 shows primers (SEQ ID NOs: 43, 44, 45, 37, 38, 39, 40, 41, 42) in order from the top, which are also used for genotyping in the Examples. , 34, 35, 36, 22, 22, 23, 24) and other conditions.
- FITC represents full-year-old restained isothiocyanate
- TxR represents Texas red
- Biotin represents bi-tin.
- FIG. 5 is a table summarizing single nucleotide polymorphisms studied in the association analysis of the examples.
- FIG. 6 is a table summarizing background data of 1620 male lesions that were subjected to association analysis in the example. Each data is expressed as mean soil standard deviation or%. In the table, * 1 indicates P ⁇ 0.0001 (for no restenosis), * 2 indicates P ⁇ 0.001 (for no restenosis), and * 3 indicates ⁇ ⁇ 0.05 (for no restenosis). ) And * 4 represents a large 0.005 (relative to no restenosis).
- FIG. 7 is a table summarizing the background data of the 771 female lesions that were subjected to the association analysis in the examples. Each data is expressed as mean soil standard deviation or%.
- * 1 is P 0 0.005 (for no restenosis)
- * 2 is P 0.05 0.05 (for no restenosis)
- * 3 is P 0.00 0.0001 (for no restenosis)
- * 4 represents P ⁇ 0.001 (for no restenosis), respectively.
- Figure 8 is a table summarizing the results of polymorphisms subjected to association analysis and the results of polynomial mouth dyistic regression analysis (male example).
- Figure 9 is a table that summarizes the results of polymorphisms and the results of multinomial logistic regression analysis (female examples) targeted for association analysis.
- Figure 10 is a table showing the results of a step forward selection method of polynomial osteotomy regression analysis for male polymorphisms associated with restenosis after coronary angioplasty (male example).
- Fig. 11 is a table showing the results (female examples) of the step forward selection method of polynomial dystopic regression analysis for genetic polymorphisms associated with restenosis after coronary angioplasty.
- FIG. 12 is a table showing the results of a genetic risk diagnosis of restenosis after balloon dilatation using five combination gene polymorphisms in men.
- Figure 13 is a table showing the results of a genetic risk diagnosis of restenosis after stent insertion using five combination gene polymorphisms in men.
- FIG. 14 is a table showing the results of a genetic risk diagnosis of restenosis after balloon dilatation using five combination gene polymorphisms in women.
- Figure 15 is a table showing the results of a genetic risk diagnosis of restenosis after insertion of a stent using the five combination gene polymorphisms in women.
- Figure 16 is a graph showing the relationship between the cumulative odds ratio of restenosis after coronary angioplasty and the number of single nucleotide polymorphisms. Restenosis after balloon dilatation is ( ⁇ ), Restenosis after stent insertion ( ⁇ ), (A) indicates association in males, (B) indicates association in females.
- SNP1 ApoE (3932T ⁇ C) polymorphism
- SNP2 GPIa (1648A ⁇ G) polymorphism
- SNP3 TNFa (-863C ⁇ A) polymorphism
- SMP4 G-protein / 33 (825C ⁇ T) polymorphism
- SNP5 ApoC-II (-482C T) polymorphism
- SNP6 AGT (-6G ⁇ A) polymorphism.
- each SP in restenosis after stent implantation is as follows: SNP1: TSP4 (1186G ⁇ C) polymorphism, SNP2: TNFa ( ⁇ 863C ⁇ A) polymorphism, SMP3: TM (2136C ⁇ T) polymorphism, SNP4: TP0 (5713A ⁇ G) polymorphism, SNP5: PAF-AH (994G ⁇ T).
- each SNP in restenosis after balloon dilatation was SNP1: E-selectin (561A ⁇ C) polymorphism, SNP2: FABP2 (2445G ⁇ A) polymorphism, SNP3: GP Ib ⁇ (1018C ⁇ T) polymorphism Type, SNP4: PAM (-668 / 4G ⁇ 5G) polymorphism, SNP5: P0M (584G ⁇ A) polymorphism, SMP6: ApoE (3932T ⁇ CPA11) polymorphism.
- SNPs in restenosis after stent insertion are SNP1: PAI1 (-668 / 4G ⁇ 5G) polymorphism, SNP2: ApoC-1 II (-482C ⁇ T) polymorphism, SMP3: PON (584G ⁇ A) polymorphism, SNP4: GPIba (1018C ⁇ T) polymorphism, SNP5: ApoE (3932TC) polymorphism.
- a first aspect of the present invention relates to a method for detecting a genotype of a nucleic acid sample.
- One embodiment of the present invention relates to a method for analyzing two or more polymorphisms selected from the group consisting of the following (1) to (6). It is characterized by including.
- Another embodiment is characterized by including a step of analyzing two or more polymorphisms selected from the group consisting of the following (7) to (11).
- Yet another embodiment is characterized by including a step of analyzing two or more polymorphisms selected from the group consisting of the following (12) to (17).
- Still another embodiment is characterized in that the method includes a step of analyzing two or more polymorphisms selected from the group consisting of the following (18) to (22).
- the genetic risk of restenosis after coronary angioplasty can be determined by determining the genotype of the nucleic acid sample from the polymorphism information obtained as a result of the above steps.
- G-protein; 83 (825C ⁇ T) polymorphism 825C ⁇ T
- TMFa (-863C ⁇ A) polymorphism Polymorphism at nucleotide number -863 of the Tumor necrosis factor- ⁇ (Tumor necrosis factor- ⁇ ) gene:-863C ⁇ A (hereinafter also referred to as “TMFa (-863C ⁇ A) polymorphism”)
- E-selectin E-selectin gene: 561A ⁇ C (hereinafter also referred to as “E-selectin (561A ⁇ C) polymorphism”)
- Plasminogen activator inh ibi tor-1 (Plasminogen activator inh ibitor-1) gene base number-Polymorphism at position 668:-668 / 4G ⁇ 5G (hereinafter, ⁇ 11 (-668 / 4G
- Apolipoprotein C-III (Apol ipoprotein C-III) gene base number -48 Polymorphism at position 2: -482C ⁇ T (hereinafter also referred to as “ApoC-l II (-482C ⁇ T) polymorphism”)
- polymorphism at nucleotide number 3932 of the apolipoprotein E gene: 3932T ⁇ C (hereinafter also referred to as “ApoE (3932T ⁇ C) polymorphism”)
- the notation means that the polymorphism at the base number position consists of two genotypes, which are bases before or after the arrow.
- -668 / 4G ⁇ 5G is a genotype in which four G (guanine) are continuously present in the 3 'direction from base number -668.
- the base number of each gene is expressed based on a known sequence registered in the public database GenBank (NCBI).
- the 3932th base is apolipoprotein E gene. Corresponds to the base at position 3232.
- SEQ ID NO: 2 accesion No.
- X17 033 M28249 Human mRNA for integrin alpha-2 subunit
- the 1648th nucleotide corresponds to the 1648th nucleotide of the glycoprotein la gene
- the nucleotide sequence of SEQ ID NO: 3 The base at position # 97 in System 1 J (Accession No. L11698: Homo sapiens tumor necrosis factor alpha gene, promoter region) corresponds to the base at position ⁇ 863 of the tumor necrosis factor a gene
- SEQ ID NO: 4 accesion No.
- M31328 In human guanine nuclein ioti de-bind ng protein beta-3 subunit mRNA, complete cds), the 831rd base corresponds to the 825th base of the G-protein j83 subunit gene, In the accession No. X13367 (SEQ ID NO: 5), the 936th base corresponds to the -48 2nd base of the apolipoprotein C-III gene in Accession No. X13367: Human DNA for apol ipoprotein Cl II 5'-flank. SEQ ID NO: 6 (Accession No. X15323: H.
- sapiens a ng io tensi nogen gene b region and exon 1) which corresponds to nucleotide position -6 of the 463th 3 ⁇ 4 street or angiotensinogen gene, and the nucleotide sequence of SEQ ID NO: 7 (Accession No. Z19585: H. sapiens mRNA) In the thrombospond i n-4), the 1186th base corresponds to the 1186th base of the trombospondin 4 gene, and the nucleotide sequence of SEQ ID NO: 8 (Accession No.
- Tsuyoshi 210 Homo sapiens gene for thrombomodul in The 2136th base in the precursor, complete cds) corresponds to the 2136th base of the thrombomodulin gene, and the 5753th base in the nucleotide sequence of SEQ ID NO: 9 (Accession No. L36051: Human thrombopoiet in gene, complete cds) Thrombopoietin gene In the base sequence of SEQ ID NO: 10 (Accession No.
- U20157 Hum an platelet-activating factor acetate I hydrolase mRNA, complete cds
- the 996th base is the platelet activating factor
- the nucleotide at position 994 in the nucleotide sequence of SEQ ID NO: 11 corresponds to nucleotide position 994 of the acetylhydrolase gene.
- ELAM-1 Human endothelia ia leukocyte adhesion molecule 1
- the 2445th base corresponds to the 2445th base of the fatty acid binding protein 2 gene, and the base number is SEQ ID NO: 13 (Accession No. J02940: Human platelet glycoprotein lb alpha chain mRNA, complete cds) In the 524th base is glycoprotein Ibex It corresponds to the 1018 base of the gene, and is the 31st base in the base sequence of SEQ ID NO: 14 (Accession No. X13323: Human gene for plasminogen activator inhibitor 1 (PA I -1)-flank and ex on 1).
- the nucleotide sequence corresponds to the nucleotide at position 668 of the plasminogen activator inhibitor ichiichi 1 gene.
- the nucleotide sequence of SEQ ID NO: 15 (Accession No. 63012: H. sapiens serum paraoxonase (PON) mRNA, complete cds)
- the 584th base corresponds to the 584th base of the para-xonase gene.
- analyzing a polymorphism means investigating the genotype of a nucleic acid sample with respect to the gene polymorphism to be analyzed, and the base at the position where the polymorphism exists (base sequence) Is equivalent to examining Typically, taking the analysis of the ApoE (3932T ⁇ C) polymorphism as an example, the genotype of apolipoprotein E in a nucleic acid sample is CC (the 3932 base is homozygous for C in both alleles) and TC (Heterozygotes of the allele of T and C allele at base 3932) and TT (homozygote of alleles at base 3932).
- the polymorphisms (1) to (6) described above indicate the genetic risk of restenosis after coronary angioplasty in an analysis of Japanese men who underwent balloon dilatation, as shown in the examples below. Is a polymorphism that has been found to be particularly effective for use in the determination of Therefore, the analysis of these polymorphisms should be performed with higher accuracy and higher predictive probability when using males (especially Japanese males) as subjects for balloon dilatation as coronary angioplasty. Make it possible.
- polymorphisms (7) to (11) described above indicate that restenosis after coronary angioplasty in an analysis of Japanese men who underwent stent insertion, as shown in the examples below. It is a polymorphism that has been found to be particularly effective when used to determine genetic risk. Therefore, analysis of these polymorphisms is intended for stent insertion as a coronary angioplasty procedure, and when using males (especially Japanese males) as subjects, diagnosis with higher accuracy and higher predictive probability is possible. Is possible.
- the above-mentioned polymorphisms (1 2) to (17) were determined by post-coronary angioplasty in an analysis of Japanese women who underwent balloon dilatation, as shown in the examples below.
- polymorphisms (18) to (22) described above show that restenosis after coronary angioplasty in an analysis of Japanese women who had stent insertion, as shown in the examples below. It is a polymorphism that has been found to be particularly effective for use in determining genetic risk. Therefore, analysis of these polymorphisms is intended for stent insertion as a coronary angioplasty procedure, and can be predicted with higher accuracy when employing women (particularly Japanese women) as subjects. Enables high-probability diagnosis.
- the genotype of the nucleic acid sample is further finely classified in proportion to the increase in the number of polymorphisms to be analyzed, whereby the genetic risk of restenosis after coronary angioplasty, which has a higher predictive probability, is increased. Can be diagnosed. From such a viewpoint, it is preferable to detect a genotype by analyzing more polymorphisms among the polymorphisms of the above ( ⁇ to (6).
- polymorphisms (1) to (6) It is most preferable to analyze all of the polymorphisms (1) to (6).
- a genotype is detected by combining five or less polymorphisms, it is preferable to preferentially select and use a polymorphism having a high odds ratio, which will be described in Examples described later.
- a polymorphism having a high odds ratio For example, if five polymorphisms are used in combination, select the five polymorphisms with the highest odds ratio, namely (1), (2), (3), '(4), and (5) Children are preferred.
- four polymorphisms are used in combination, it is preferable to select (1), (3), (4), and (5).
- polymorphisms (7) to (11) when analyzing two or more polymorphisms selected from the polymorphisms (7) to (11), it is most preferable to analyze all these polymorphisms, ie, five polymorphisms.
- a genotype is detected by combining four or less polymorphisms, it is preferable to preferentially select and use a polymorphism having a high head ratio as described in Examples described later. For example, if four polymorphisms are used in combination, it is preferable to select the four polymorphisms with higher odds ratios, ie, (7), (8), (9), and (10). Similarly, if, for example, three polymorphisms are used in combination, it is preferable to select (7), (8), and (9).
- polymorphisms (12) to (17) when analyzing two or more polymorphisms selected from the polymorphisms (12) to (17), it is most preferable to analyze all these polymorphisms, that is, six polymorphisms.
- a genotype is detected by combining five or less polymorphisms, it is preferable to preferentially select and use a polymorphism having a high odds ratio, which will be described in Examples below. For example, if five polymorphisms are used in combination, select the five polymorphisms with the highest odds ratio, ie, (12), (13), (14), (15), and (16) Is preferred.
- polymorphisms (18) to (22) when analyzing two or more polymorphisms selected from the polymorphisms (18) to (22), it is most preferable to analyze all these polymorphisms, ie, five polymorphisms.
- a genotype is detected by combining four or less polymorphisms, it is preferable to preferentially select and use a polymorphism having a high head ratio as described in Examples described later. For example, if four polymorphisms are used in combination, it is preferable to select the four polymorphisms with the highest head ratio, ie, (18), (19), (20), and (21). Similarly, if, for example, three polymorphisms are used in combination, it is preferable to select (18), (19), and (20).
- the method for analyzing each gene polymorphism is not particularly limited. For example, amplification by PCR method using aryl specific primers (and probes), and a method for analyzing the polymorphism of the amplified product by fluorescence or luminescence, PCR-polymerase chain reaction (PCR) -RFLP (restriction fragment length poIymo rph ism: restriction enzyme fragment length polymorphism) method, PCR-SSCP (single strand conformation poIymo rph ism: single chain) Higher order structure Natl. Acad.
- PCR-RFLP restriction enzyme fragment length polymorphism
- PCR-SSCP single strand conformation poIymo rph ism: single chain
- analysis may be performed by directly sequencing the polymorphic portion to be analyzed.
- the polymorphism analysis may be performed by arbitrarily combining these methods.
- a method using a PCR method for example, PCR-RFLP method
- any of the above analysis methods can be applied after the nucleic acid sample has been amplified (including amplification of a partial region of the nucleic acid sample) in advance by a gene amplification method such as a method applying the PCR method or the PCR method.
- nucleic acid for polymorphism analysis examples include a nucleic acid having a sequence complementary to a certain region (partial DNA region) containing the polymorphic site in a gene containing the polymorphism to be analyzed.
- the gene containing the polymorphism to be analyzed has a sequence complementary to a certain region (partial DNA region) containing the polymorphism site, so that a DNA fragment containing the polymorphism portion can be specifically amplified.
- Nucleic acids (primers) designed as described above can be mentioned.
- nucleic acid for example, when the polymorphism at position 3932 of the apolipopin tin E gene is to be analyzed, a portion containing the base at position 3932 of the apolipoprotein E gene in which the base at position 3932 is T (thymine)
- a nucleic acid having a sequence complementary to the DMA region, or a nucleic acid having a sequence complementary to the partial DMA region containing the base at position 3932 of the apolipopin tin E gene in which the base at position 3932 is C (cytosine) is applicable.
- nucleic acid for polymorphism analysis is to design a specific DNA region containing the polymorphic site only when the polymorphic site to be analyzed is any of the genotypes.
- nucleic acid set include: More specifically, a nucleic acid set designed to specifically amplify a partial DMA region containing a polymorphic site to be analyzed, wherein the polymorphic site is an antisense strand having any genotype.
- nucleic acid set include a sense primer specifically hybridizing to a partial DNA region containing the polymorphic site and an antisense primer specifically hybridizing to a partial region of a sense strand. .
- the partial DMA region containing the base 3939 of the apolipoprotein E gene should be specifically amplified. Designed to A sense primer and a sense strand that specifically hybridize to the partial DNA region containing the 3932 base in the antisense strand of the apolipoprotein E gene in which the 3932 base is T (thymine).
- a nucleic acid set consisting of an antisense primer that hybridizes specifically to a partial region of the apolipoprotein E gene in which the 3932th base is C (cytosine), or a partial DNA containing the 3932th base in the antisense strand of the apolipoprotein E gene
- the nucleic acid set includes a sense primer specifically hybridizing to a region and an antisense primer specifically hybridizing to a partial region of the sense strand.
- the length of the partial DNA region to be amplified is appropriately set within a range suitable for the detection, and is, for example, 50 bp to 200 bp, preferably 80 bp to 150 bp.
- nucleic acid primer for ApoE 3932T ⁇ C
- ApoE 3932T ⁇ C
- the underlined portions in the following sequences represent portions corresponding to polymorphisms.
- N in the sequence means any of A, T, C, and G.
- GGACATGGAGGACGTI ⁇ G SEQ ID NO: 16, or
- CGCGGTACTGCACCAGGC SEQ ID NO: 18
- a nucleic acid primer having the following sequence as an example of a nucleic acid primer for GPI a (1648A ⁇ G) polymorphism analysis can be exemplified.
- GAGTCTACCTGTTTACTATCAANAA SEQ ID NO: 19, or
- GAGTCTACCTGTTTACTATCAANGA SEQ ID NO: 20
- Antisense primer ACCAGTACTAAAGCAAATTAAACT SEQ ID NO: 21 Similarly, as a nucleic acid primer for TMFa (-863C ⁇ A) polymorphism analysis, one having the following sequence can be exemplified.
- GGCCCTGTCTTCGTTAANGG SEQ ID NO: 22, or
- ATGGCCCTGTCTTCGTTAANTG SEQ ID NO: 2 3 '
- nucleic acid primers for G-protein j83 (825C ⁇ T) polymorphism analysis which have the following sequences can be exemplified.
- GAATAGTAGGCGGCCACTGA SEQ ID NO: 27
- ApoC-1II 482C ⁇ T
- TGTTTGGAGTAAAGGCACAGAA SEQ ID NO: 30
- a nucleic acid primer for AGT (-6G ⁇ A) polymorphism analysis having the following sequence can be exemplified.
- CGGCAGCTTCTTCCCNCG SEQ ID NO: 31 or
- CCACCCCTCAGCTATAAATAGG SEQ ID NO: 33
- TSP4 n86G ⁇ C
- GGTCTGCACTGACATTGATGAG SEQ ID NO: 36
- a nucleic acid primer having the following sequence can be exemplified.
- CCCGACTCGGCCCTTMCC SEQ ID NO: 37, or
- CCCGACTCGGCCCTTWTC SEQ ID NO: 38
- GTCACAGTCGGTGCCAATGT SEQ ID NO: 39
- TP0 5713A ⁇ G polymorphism analysis
- CCGACATCAGCATTGTCTNAT SEQ ID NO: 40, or
- CTGCAGGGAAGGGAGCTGT SEQ ID NO: 42
- a nucleic acid primer for PAF-AH (994G ⁇ T) polymorphism analysis having the following sequence can be exemplified.
- TTCTTTTGGTGGAGCAACNGT SEQ ID NO: 43, or
- TCTTACCTGAATCTCTGATCTTCA SEQ ID NO: 45
- E-selectin 561 A ⁇ C
- ACATTCACCGTGGCCANIG SEQ ID NO: 46, or
- AGCTGCCTGTACCAATACATCC SEQ ID NO: 48
- nucleic acid primer for FABP2 (2445G ⁇ A) polymorphism analysis has the following sequence: Can be exemplified.
- TCACAGTCAAAGAATCAAGNGC SEQ ID NO: 49, or
- nucleic acid primer having the following sequence can be exemplified as a nucleic acid primer for GPI ba (1018C ⁇ T) polymorphism analysis.
- CCCAGGGCTCCTGNCG SEQ ID NO: 52, or
- TGAGCTTCTCCAGCTTGGGTG: SEQ ID NO: 54 one having the following sequence can be exemplified as a nucleic acid primer for PAM (-668 / 4G-5G) polymorphism analysis.
- GGCACAGAGAGAGTCTGGACACG SEQ ID NO: 55 '
- GGCCGCCTCCGATGATACA SEQ ID NO: 56
- P0N 584G ⁇ A
- Sense Primer ACCCAAATACATCTCCCAGGANCG SEQ ID NO: 57, or
- AACCCAAATACATCTCCCAGGNCT SEQ ID NO: 58
- GAATGATATTGTTGCTGTGGGAC SEQ ID NO: 59
- CACCGTGGCCANTGCAGGAT SEQ ID NO: 62, or
- CACCGTGGCCANGGCAGGAT SEQ ID NO: 63.
- GAATCAAGNGCTTTTCGAAACATT SEQ ID NO: 64, or
- GAATCAAGNACTTTTCGAAACATT SEQ ID NO: 65.
- PA I 1 (-668 / 4G ⁇ 5G) as a probe for polymorphism analysis
- TGGACACGTGGGGGAGTCAG SEQ ID NO: 66, or
- nucleic acid primers and nucleic acid probes are merely examples, as long as nucleic acid primers can perform the desired amplification reaction without hindrance, and nucleic acid probes can perform the desired hybridization reaction without hindrance.
- Some salt The base sequence may be modified.
- “partially modified” means that a part of the base has been deleted, substituted, inserted and / or added.
- the number of bases to be modified is, for example, 77, preferably ⁇ -5, and more preferably 1-3. In addition, such a modification is performed in a portion other than the base corresponding to the polymorphic site in principle.
- the polymorphism to be analyzed is a PAI 1 (-668 / 4G ⁇ 5G) polymorphism
- a nucleic acid obtained by modifying a part of the base corresponding to the polymorphic site is used as a primer or a probe. It is also possible. DNA fragments or RNA fragments are used as appropriate for the polymorphism analysis nucleic acid (probe, primer) depending on the analysis method.
- the base length of the nucleic acid for polymorphism analysis may be any length as long as each function is exhibited, and examples of the base length when used as a primer are about 10 to 50 bp, preferably about 15 to 40 bp, more preferably It is about 15 to 30 bp.
- mismatch When used as a primer, there may be some mismatch with the type II sequence as long as it hybridizes specifically to the amplification target and can amplify the target DNA fragment. Similarly, in the case of a probe, there may be some mismatch with respect to the sequence to be detected as long as it can specifically hybridize with the sequence to be detected.
- the degree of mismatch is one to several, preferably one to five, and more preferably one to three.
- Nucleic acids for polymorphism analysis can be synthesized by a known method such as the phosphodiester method. Regarding the design, synthesis, and the like of the nucleic acid for polymorphism analysis, reference can be made to books (eg, Molecular Cloning, Third Edition, Cold Spring Harbor Laboratory Press, New York).
- the nucleic acid for polymorphism analysis in the present invention can be labeled in advance with a labeling substance. By using such a labeled nucleic acid, polymorphism analysis can be performed using, for example, the labeling amount of the amplification product as an index.
- amplification products can be obtained.
- the genotype of the nucleic acid sample can be determined based on the detected labeling substance and labeling amount.
- Specific examples of detection methods using such labeled primers include two types of nucleic acid primers (aryl-specific sense primers) that specifically hybridize to the sense strand of each genotype constituting the polymorphism.
- Primer is labeled with a full-year restained isocyanate isoform and a Texas red, respectively, and a partial DNA region containing a polymorphic site is obtained using these labeled primers and an antisense primer that specifically hybridizes to the antisense strand. And a method of detecting the polymorphism by measuring the amount of labeling of each fluorescent substance in the obtained amplification product. If the antisense primer is labeled with, for example, virgin, amplification products can be separated using specific binding between biotin and avidin.
- labeling substances used for labeling nucleic acids for polymorphism analysis include radioisotopes such as 32 P, fluorescent substances such as full-year reseicin isothiocyanate, tetramethyl rhodamine isothiane cyanate, and Texas red.
- Labeling methods include 5 'end labeling using alkaline phosphatase and T4 polynucleotide kinase, 3' end labeling using T4 DNA polymerase ⁇ Klenow fragment, nick translation method, random primer method (Mol ecular Cloning, Third Edition, Chapter 9, Cold Spring Harbor Laboratory Press, New York).
- the above-described nucleic acid for polymorphism analysis can be used in a state immobilized on an insoluble support.
- the nucleic acid sample can be prepared from a subject's blood, skin cells, mucous membrane cells, hair, and the like using known extraction methods and purification methods. Any length of genomic DNA can be used as a nucleic acid sample as long as it contains a gene to be subjected to polymorphism analysis. Also, it is not necessary to use a nucleic acid sample in which all the genes to be analyzed are present on one nucleic acid.
- nucleic acid sample of the present invention any of those in which all of the genes to be analyzed are present on one nucleic acid, and those in which the genes to be analyzed are separately present on two or more nucleic acids are used. Can be used. It should be noted that even if the gene to be analyzed in the nucleic acid sample is not in an intact state (that is, in a state where the full length of the gene is present), fragmentation or partial fragmentation may occur as long as at least the polymorphic site to be analyzed exists. It may be in the state. Analysis of each gene polymorphism is performed for each gene polymorphism, or a plurality or all of them are simultaneously performed.
- nucleic acid sample obtained from a subject is dispensed according to the number of polymorphisms to be analyzed, and each polymorphism is individually analyzed.
- DNA chip or microarray can be used.
- the term “simultaneous” as used herein does not only mean that all operations in the analysis process are performed simultaneously, but also that some operations (for example, nucleic acid amplification operation, probe hybridization, or detection) are performed simultaneously. Including cases. Polymorphism of each gene can also be analyzed using mRNA which is a transcription product of the gene to be analyzed. For example, after extracting and purifying the mRNA of the gene to be analyzed from the blood, urine, etc.
- Methods of analyzing using the expression products of such genes include a method of directly analyzing the amino acid at the polymorphic site, and a method of performing an immunological analysis using a change in the three-dimensional structure.
- a well-known amino acid sequence analysis method (a method using the Edman method) can be used.
- the latter includes an ELISA method (enzyme-linked immunosorbent assay) using a monoclonal antibody or a polyclonal antibody having a specific binding activity to the expression product of a gene having any genotype constituting the polymorphism.
- Radioimmunoassay, immunoprecipitation, immunodiffusion, and the like can be used.
- the polymorphism information obtained by executing the above-described detection method of the present invention can be used for diagnosis of a genetic risk of restenosis after coronary angioplasty. That is, the present invention comprises the steps of determining the genotype of a nucleic acid sample from the polymorphism information obtained by the above detection method, and determining the genetic risk from the determined genotype of the nucleic acid sample.
- a method for diagnosing the risk of restenosis after plastic surgery is also provided.
- the genotype determination here typically involves determining which allele of the nucleic acid sample is associated with the polymorphism to be detected. Is determined to have each genotype.
- the genotype of apolipoprotein E in a nucleic acid sample is TT (homozygous for both allele T at position 3932).
- CT base 3293 is a heterozygote of the T allele and C allele
- CC base 3932 is a homozygote of both alleles C.
- the ApoE (3932T ⁇ C) polymorphism it is determined whether the genotype of the nucleic acid sample is CC or TC or TT.
- the GP I a (1648A ⁇ G) polymorphism is GG, or it is either AG or AA, or if the TNF a (-863C ⁇ A) polymorphism is AA or CA, Either one, CC or G-protein / 3 3 825C ⁇ T) polymorphism, TT, or CT or CC, ApoC-1 II (- 482 C ⁇ T) If the polymorphism is either TT or CT, or CC, or TT, or CT or CC, AGT (-6G-A ) If it is a polymorphism, it is either AA or GA, or GG, if it is a TSP4 (1 186G ⁇ C) polymorphism, it is either CC or GC, or GG, TM (2136C ⁇ T) polymorphism is either TT or CT or CC or TP0 (571 3A ⁇ G) polymorphism is GG or AG or AA Either, or PAF
- Diagnosis of the genetic risk of restenosis after coronary angioplasty predicts the likelihood (probability) of restenosis after coronary angioplasty. That is, the risk of restenosis after coronary angioplasty can be evaluated by the diagnostic method of the present invention. Being able to make such an evaluation is extremely clinically significant because it allows the selection of appropriate treatment in advance. Utilizing the genetic information related to the occurrence of restenosis obtained by the present invention, the incidence of restenosis after coronary angioplasty can be reduced.
- the polymorphism to be analyzed is a genotype that increases the risk of restenosis as a result of performing the diagnostic method of the present invention
- a gene having a genotype with a low onset risk for the polymorphism is introduced into a living body. If introduced, the expression of the gene can be expected to reduce the risk of restenosis.
- a similar effect can be expected by introducing an antisense chain to the mRNA of a gene having a genotype having a high risk of restenosis and suppressing the expression of the mRNA.
- Such a gene or the like can be introduced into a living body by, for example, a method using a plasmid for gene transfer or a virus vector, an electoral poration (Potter, ⁇ ⁇ et al., Proc. Natl. Acad. Acad. Sci. USA 81, 7161-7165 (1984)), ultrasonic microbubbles (Lawrie, A., et al. Gene Therapy 7, 2023-2027 (2000)), lipofection (Fe Igner, PL et a, Proc. Nat I Acad. Sci. USA 84, 7413-7417 (1984)), microinjection (Graessmann, M. & Graessmann, A., Proc. Nat I. Acad. Sci. USA 73, 366-370 (1976)). It can be done by a method. Introduction of genes and the like using these methods can be performed directly (in vivo method) or indirectly (e. x vivo method).
- a gene or the like may be coated in advance (a plasmid for gene transfer or a vector retained in a virus vector may be coated).
- a device such as a stent may be used simultaneously with or after coronary angioplasty. Gene transfer as described above can also be performed.
- a kit a kit for genotype detection or a kit for diagnosing restenosis after coronary angioplasty used in the above-described detection method or diagnosis method of the present invention.
- a kit includes a nucleic acid (polymorphism analysis nucleic acid) for analyzing two or more polymorphisms selected from the group consisting of the above polymorphisms (1) to (6).
- the kit includes a nucleic acid (polymorphism analysis nucleic acid) for analyzing two or more polymorphisms selected from the group consisting of the above polymorphisms (7) to (11). Constructed.
- the kit includes a nucleic acid (polymorphism analysis nucleic acid) for analyzing two or more polymorphisms selected from the group consisting of the polymorphisms of the above (12) to (17). Is constructed.
- the kit includes a nucleic acid (polymorphism analysis nucleic acid) for analyzing two or more polymorphisms selected from the group consisting of the above polymorphisms (18) to (22). Be built.
- the nucleic acid for polymorphism analysis is analyzed using the analysis method to which it is applied (eg, the method using the PCR method using an aryl-specific nucleic acid, the PCR-RFLP method, the PCR-SSCP, the TaqMan-PCR method, the Invader method, etc.). in), it is designed as capable of specifically amplifying m RN a corresponding to the DMA area or containing the polymorphic portion to be analyzed (primer I) or specifically it can detect (probe).
- the kit provided in the present invention are shown. It comprises two or more nucleic acids selected from the group consisting of the following (1) to (6) Genotype detection kit,
- a nucleic acid having a sequence complementary to the DNA region containing the 3932 base of the apolipoprotein E gene in which the 3932 base is T, or the 3932 position of the apolipoprotein E gene in which the 3932 base is C A nucleic acid having a sequence complementary to a partial DNA region containing bases; (2) a nucleic acid having a sequence complementary to a partial DNA region containing bases 1648 of the glycoprotein la gene in which base 1648 is A; Or a nucleic acid having a sequence complementary to a partial DNA region containing the 1648th base of the glycoprotein la gene in which the 1648th base is G,
- G-protein whose base 825 is C; nucleic acid having a sequence complementary to the partial DMA region containing base 825 of 83subunit gene, or G-protein whose base 825 is T a nucleic acid having a sequence complementary to the partial DMA region containing the base at position 825 of the j83 subunit gene,
- A-polypoprotein having a base at position -482 is C.
- a nucleic acid having a sequence complementary to the partial DMA region containing the -482 base of the C-1 II gene, or an apolipoprotein having a base at -482 is T.
- two or more nucleic acids are selected from the group consisting of (1) to (6) to form a kit.
- the kit may be constituted by selecting two or more nucleic acids from such a group.
- a nucleic acid set for analyzing the top 5 polymorphisms to construct a kit by selecting two or more nucleic acids, or from (1), (3), (4), and (5)
- a kit can be constructed by selecting two or more nucleic acids from a certain group (nucleic acids for analyzing polymorphisms having the highest four odds ratios in the examples described later).
- a genotype detection kit comprising two or more nucleic acids selected from the group consisting of the following (7) to 1):
- nucleic acid having a sequence complementary to the partial DNA region containing the base 2136 of the thrombomodulin gene in which the base 2136 is C, or the base 2136 of the thrombomodulin gene in which the base 2136 is T A nucleic acid having a sequence complementary to the partial DNA region
- a nucleic acid having a sequence complementary to the DNA region containing the base at position 5713 of the trombopopoietin gene in which the base at position 5713 is A, or base 5713 of the trumpopopoietin gene in which the base at position 5713 is G A nucleic acid having a sequence complementary to the partial DMA region, and
- a nucleic acid having a sequence complementary to the partial DNA region containing the 994th base of the platelet activating factor acetylhydrolase gene in which the 994th base is G, or a platelet activating factor in which the 994th base is T A nucleic acid having a sequence complementary to a partial DNA region containing the base at position 994 of the cetyl hydrolase gene.
- two or more nucleic acids are selected from the group consisting of (7) to (11) and the kit is selected.
- the kit may be constituted by arbitrarily selecting two or more of (7) to (11) to form a group and selecting two or more nucleic acids from such a group to constitute a kit.
- two or more nucleic acid sets are selected from Darup (7) to (10) (nucleic acids for analyzing polymorphisms having the top four rankings in Examples described later).
- a group consisting of (7) to (9) a nucleic acid for analyzing polymorphisms having the top three odds ratios in the examples described later). You can select and configure the kit.
- a genotype detection kit comprising two or more nucleic acids selected from the group consisting of the following (12) to 7):
- a nucleic acid having a sequence complementary to the partial DNA region containing the base 561 of the E-selectin gene in which the base 561 is A, or the base 561 of the E-selectin gene in which the base 561 is C A nucleic acid having a sequence complementary to the partial DMA region,
- nucleic acid having a sequence complementary to the partial DNA region containing the 1018 base of the Dalicoprotein Ibex gene whose C base at position 1018 is C, or the 1018 base of Glycoprotein Tin Ibex gene whose T base at position 1018 is T A nucleic acid having a sequence complementary to a partial DNA region containing
- two or more nucleic acids are selected from the group consisting of (12) to (17) to constitute a kit, but two or more of (12) to (17) may be arbitrarily selected.
- a kit may be formed by selecting a group and selecting two or more nucleic acids from the group.
- two or more nucleic acids are selected from the group consisting of (12) to (16) (nucleic acids for analyzing polymorphisms with the top five in the examples described below) and the kit is selected.
- a nucleic acid composed of (12) to (15) (a nucleic acid having an odds ratio of up to 4 in the following examples), and a kit consisting of at least two lini nucleic acids. can do.
- a genotype detection kit comprising two or more nucleic acids selected from the group consisting of the following (18) to (22):
- a nucleic acid having a sequence complementary to the partial DNA region containing the 584th base of the para-xenonase gene whose 584th base is G, or the 584th base of the paralyxonase gene whose 584th base is A A nucleic acid having a sequence complementary to a partial DNA region containing
- nucleic acid having a sequence complementary to the partial DNA region containing the 3932 base of the apolipoprotein E gene in which the 3932 base is T, or the 3932 base of the apolipoprotein E gene in which the 3932 base is C A nucleic acid having a sequence complementary to a partial DMA region.
- two or more nucleic acids are selected from the group consisting of (18) to (22) to form a kit.
- the kit may be constituted by selecting two or more nucleic acids from the group.
- two or more nucleic acid sets are selected from the group consisting of (18) to (21) (nucleic acids for analyzing polymorphisms having the top four in the examples below).
- Two or more nucleic acids are included in a kit or a group consisting of (18) to (20) (nucleic acids for analyzing polymorphisms with the highest odds ratio in the examples described below). You can select and configure the kit.
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (1) to (6):
- the nucleic acid set designed to specifically amplify the partial DMA region containing the base 3932 of the apolipoprotein ⁇ gene, or the base 3939 of the apolipoprotein E gene in the nucleic acid sample is C Only in this case, a nucleic acid set designed to specifically amplify the partial DNA region containing the base 3932 of the apolipoprotein E gene, (2) position 1648 of the glycoprotein la gene in the nucleic acid sample Only when the base is A, is the nucleic acid set designed to specifically amplify the partial DNA region containing the base at position 1648 of the glycoprotein la gene, or of the glycoprotein la gene in the nucleic acid sample.
- the partial DNA region containing the 825th base of the G-protein ⁇ 3 subunit gene can be specifically identified. Only when the position 825 of the G-protein ⁇ 3 subunit gene in the nucleic acid set or nucleic acid sample designed to amplify is ⁇ , the position 825 of the G-protein ⁇ 3 subunit gene A nucleic acid set designed to specifically amplify a partial DNA region containing
- the partial DNA region containing the -482 base of the apolipoprotein C-1 II gene is specifically identified.
- -482 position of the apolipoprotein C-1II gene only when the base at position -482 of the apolipopin C-1II gene in the nucleic acid set or nucleic acid sample designed to amplify Designed to specifically amplify the partial DMA region containing bases Nucleic acid set, and
- the partial DNA region containing the ⁇ 6 base of the angiotensinogen gene can be specifically amplified.
- nucleic acid set c and above designed in the above two or more nucleic acid sets are selected from the group consisting of (1) to (6) to form a kit, but (1) to (6) Two or more of these may be arbitrarily selected to form a group, and two or more nucleic acid sets may be selected from such a group to constitute a kit.
- a group consisting of (1) to (5) (a nucleic acid set for analyzing the top 5 polymorphisms selected in consideration of the odds ratio and P value in the examples described later).
- a kit is constructed by selecting at least two lini nucleic acid sets, or a group consisting of (1), (3), (4), and (5).
- Nucleic acid set for analyzing polymorphisms up to the order It is possible to construct a kit by selecting two or more nucleic acid sets.
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (7) to (11):
- Tumor necrosis factor 0 in the nucleic acid sample Only when the ⁇ 863 base of the gene is C, specifically amplifies the partial DNA region containing the ⁇ 863 base of the tumor necrosis factor a gene Only when the ⁇ 863 base of the tumor necrosis factor a gene in the nucleic acid set or nucleic acid sample designed as described above is A, the partial DNA region containing the ⁇ 863 base of the tumor necrosis factor ⁇ gene is Nucleic acid sets designed to specifically amplify,
- a kit is configured by selecting two or more nucleic acid sets from the group consisting of (7) to (11).
- the kit may be constituted by selecting two or more nucleic acid sets from the group.
- two or more nucleic acid sets from the group consisting of (7) to (10) (a nucleic acid set for analyzing polymorphisms in the top four in the examples below) are analyzed.
- the kit can be selected to form a kit, or a group consisting of (7) to (9) (in the following examples,
- the kit can be constructed by selecting two or more nucleic acid sets from the nucleic acid sets for analyzing the top three polymorphisms.
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (12) to (17):
- the gene for the plasminogen activator inhibitor 1 gene is present only when four Gs are continuously present in the 3 ′ direction from position 668.
- Specific amplification of partial DMA region including sequence portion Plasminogen activator inhibitor 1 gene in a nucleic acid set or a nucleic acid sample designed to perform plasminogen activator inhibitor 1 gene only when five Gs are present continuously in the 3 ′ direction from position ⁇ 668.
- nucleic acid sets from a group consisting of (12) to (16) (a nucleic acid set for analyzing polymorphisms having the top five odds ratios in the examples described later) are used.
- a kit can be constructed by selecting two or more nucleic acid sets.
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (18) to (22): (18) Plasminogen activator inhibitor 1 in the nucleic acid sample only in the case where four Gs are continuously present in the 3 ′ direction from position ⁇ 668 in the gene 1 In the nucleic acid set designed to specifically amplify the partial DNA region containing the sequence portion of the gene, or the plasminogen activator inhibitor 1 gene in the nucleic acid sample-From position -668 to 3 'direction A nucleic acid set designed to specifically amplify a partial DNA region containing the sequence portion of the plasminogen activator inhibitor 1 gene only when there are five Gs in a row.
- nucleotide at position 3932 of the apolipoprotein E gene in the nucleic acid sample is T Only when the nucleic acid set designed to specifically amplify the partial DNA region containing the 3932 base of the apolipopin tin E gene, or when the 3932 base of the apolipoprotein E gene in the nucleic acid sample is C Only the nucleic acid set designed to specifically amplify the partial DNA region containing the 3932th base of the apolipopin tin E gene (in the above, two from the group consisting of (18) to (22)
- a kit is constructed by selecting the above nucleic acid sets, and two or more of (18) to (22) are arbitrarily selected to form a group, and two or more nucleic acid sets are selected from the group.
- a group consisting of (18) to (21) (a nucleic acid for analyzing polymorphisms having the top four in the head ratio in the examples described later) may be selected.
- Set) Select two or more nucleic acid sets from Or two or more nucleic acid sets from the group consisting of (18) to (20) (a nucleic acid set for analyzing polymorphisms with the highest odds ratio in the examples described below).
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (1) to (6):
- a sense primer that specifically hybridizes to the partial DNA region containing bases and / or a sense that specifically hybridizes to the partial DNA region containing base 3932 in the apolipoprotein E gene where the 3932 base is C A nucleic acid set comprising: a primer; an antisense primer that specifically hybridizes to a partial region of the apolipoprotein E gene;
- An antisense primer that specifically hybridizes to and / or a partial DNA region containing the ⁇ 863 base in the tumor necrosis factor a gene in which the ⁇ 863 base is ⁇ A nucleic acid set comprising: an antisense primer that specifically hybridizes to a gene; and a sense primer that specifically hybridizes to a partial region of the tumor necrosis factor ⁇ gene.
- G-protein j8 A nucleic acid set designed to specifically amplify the partial DNA region containing the 825th base of the j83 subunit gene, wherein G-protein 3 has a C at the 825th base.
- a sense primer that specifically hybridizes to the partial DNA region containing the 825th base in the submitt gene and / or a partial DMA region containing the 825th base in the G-protein ⁇ 3 submitt gene where the 825th base is T
- a nucleic acid set consisting of: a sense primer that specifically hybridizes to, and an antisense primer that specifically hybridizes to a partial region of the G-protein ⁇ 3 subunit gene.
- a sense primer that specifically hybridizes to the partial DMA region containing the -482 base in the protein C-III gene and / or T is the -482 base.
- nucleic acid set designed to specifically amplify the partial DNA region containing the base at position 6 in the angiotensinogen gene, wherein the nucleic acid set in the angiotensinogen gene whose base at position -6 is G is-
- An antisense primer that specifically hybridizes to a partial DNA region containing a base at position 6 and / or a partial DNA region containing base at position ⁇ 6 in an angiotensin gene that has base A at position A
- a nucleic acid set comprising: an antisense primer that hybridizes specifically and specifically; and a sense primer that specifically hybridizes to a partial region of the angiotensinogen gene.
- kits are configured by selecting two or more nucleic acid sets from the group consisting of (1) to (6), but two or more of (1) to (6) are arbitrarily selected.
- a kit may be formed by selecting two or more sets of nucleic acids from such a group. For example, a group consisting of (1) to (5) (a nucleic acid set for analyzing the top 5 polymorphisms selected in consideration of the odds ratio and P value in the examples described later)
- a kit can be constructed by selecting two or more nucleic acid sets, or a group consisting of (1), (3), (4), and (5). Nucleic acid set for analyzing polymorphisms up to the order)
- the kit can be composed by selecting two or more nucleic acid sets.
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (7) to (11):
- a nucleic acid set comprising: an antisense primer that specifically hybridizes to a primer; and a sense primer that specifically hybridizes to a partial region of the tumor necrosis factor ⁇ gene.
- Sense primer and specifically high Buridizu for the partial DNA region including 571 3-position base Te Roh or 571 3-position base is G Toronbopoi Nucleic acid consisting of a sense primer that specifically hybridizes to a partial DMA region containing the 571-position 3 base in the genetic protein gene, and an antisense primer that specifically hybridizes to a partial region of the thrombopoietin gene Set, and
- a nucleic acid set comprising: an antisense primer that specifically hybridizes to a partial region of the activation factor acetylhydrolase gene;
- a kit is configured by selecting two or more nucleic acid sets from the group consisting of (i) to ( ⁇ ), but two or more of (to) to (11) are arbitrarily selected.
- a kit may be formed by selecting two or more nucleic acid sets from such a group. For example, two or more nucleic acid sets are selected from a Darup consisting of (7) to (10) (a nucleic acid set for analyzing polymorphisms having the highest four odds ratios in the examples described later).
- a group consisting of (7) to (9) (a nucleic acid set for analyzing polymorphisms with the top three in the examples below).
- a kit can be constructed by selecting the above nucleic acid sets.
- a genotype detection kit containing two or more nucleic acid sets selected from the group consisting of the following (1 2) to (17):
- a nucleic acid set comprising: an antisense primer that hybridizes specifically and specifically; and a sense primer that specifically hybridizes to a partial region of the E-selectin gene.
- a nucleic acid set comprising: a hybridizing sense primer; an antisense primer that specifically hybridizes to a partial region of the fatty acid binding protein 2 gene;
- a partial DNA region containing a base position 3932 in the sense primer 1 and / or the apolipopin tin E gene in which the position 3932 is C which specifically hybridizes to a partial DNA region containing
- a nucleic acid set comprising: a sense primer that hybridizes; and an antisense primer that specifically hybridizes to a partial region of the apolipoprotein E gene.
- two or more nucleic acid sets are selected from the group consisting of (1 2) to (17) to constitute a kit.
- the kit may be arbitrarily selected to form a group, and two or more nucleic acid sets may be selected from the group to constitute a kit.
- two or more nucleic acid sets from the group consisting of (1 2) to (16) (a nucleic acid set for analyzing polymorphisms with the top five in the examples below) are analyzed.
- the kit can be selected to form a kit, or a group consisting of (12) to (15) (
- a kit can be constructed by selecting two or more nucleic acid sets from the nucleic acid sets for analyzing polymorphisms with the top four odds ratios).
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (18) to (22):
- apolipoprotein A nucleic acid set designed to specifically amplify a partial DNA region containing the -482 base of the C-1II gene, wherein the apo-base has a -482 base C.
- a partial DNA region containing the -482 base in the lipoprotein C-III gene, a sense primer that specifically hybridizes to and / or a -482 base in the apolipoprotein C-III gene in which the -482 base is T A nucleic acid set comprising: a sense primer that specifically hybridizes to a partial DNA region, and an antisense primer that specifically hybridizes to a partial region of the apolipoprotein C-III gene.
- a nucleic acid comprising: a sense primer that specifically hybridizes to a partial DMA region containing the 584th base in the gene; and an antisense primer that specifically hybridizes to a partial region of the para-xonase gene.
- a nucleic acid set comprising: a sense primer; and an antisense primer that specifically hybridizes to a ⁇ region of the Daricoprotein Iba gene, and
- (22) A nucleic acid set designed to specifically amplify a partial DNA region containing the 3932 base of the apolipoprotein E gene, wherein the 3932 base is T in the apolipoprotein E gene.
- Sense primer that specifically hybridizes to the partial DNA region containing the DNA and / or the sense that specifically hybridizes to the partial DNA region containing the 3932 base in the apolipoprotein E gene where the 3932 base is C
- a nucleic acid set comprising a primer and an antisense primer that specifically hybridizes to a partial region of the apolipoprotein E gene.
- kits are configured by selecting two or more nucleic acid sets from the group consisting of (18) to (22), but two or more of (18) to (22) are arbitrarily selected.
- a kit may be formed by selecting two or more nucleic acid sets from such a group. For example, two or more nucleic acid sets are selected from a group consisting of (18) to (21) (a nucleic acid set for analyzing polymorphisms with the highest four odds ratios in the examples described later) and a kit is selected. Or a group consisting of (18) to (20).
- a kit can be constructed by selecting two or more nucleic acid sets from the nucleic acid sets for analyzing polymorphisms with the top three odds ratios).
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (1) to (6):
- a nucleic acid set comprising: a third nucleic acid capable of specifically amplifying a partial DNA region containing base 3932 of the gene;
- the antisense strand of the glycoprotein Ia gene in which the base at position 1648 is A it specifically hybridized to the partial region containing the base at position 1648 and was labeled with the first labeling substance. Specifically hybridizes to the first nucleic acid and the partial region containing the 1648th base in the antisense strand of glycoprotein la gene where the 1648th base is G, and is labeled with the second labeling substance.
- the first nucleic acid or the first nucleic acid or the 1648th position of the glycoprotein la gene which is used together with the second nucleic acid and specifically hybridizes to a partial region of the sense strand of the glycoprotein la gene.
- a nucleic acid set comprising: a third nucleic acid capable of specifically amplifying a partial DNA region containing bases;
- the region specifically hybridizes to the -863 position containing the base and is labeled with the first labeling substance.
- a second labeling substance that specifically hybridizes to the identified first nucleic acid and a partial region containing the base at position ⁇ 863 in the sense strand of the tumor necrosis factor ⁇ gene where -86 is base A at position ⁇ 86.
- a second nucleic acid that is specifically hybridized to a partial region of the antisense chain of the tumor necrosis factor a gene, and is used together with the first nucleic acid or the second nucleic acid to form a tumor necrosis factor.
- a third nucleic acid capable of specifically amplifying a partial DNA region containing a base at position ⁇ 863 of the at gene; and a nucleic acid set comprising:
- a specific region hybridizing to the partial region containing the 825th base in the antisense strand of the G-protein 3 subunit gene in which the 82th base is C is labeled with the first labeling substance.
- the second nucleic acid thus obtained, and a G-protein which specifically hybridizes to a partial region of the sense strand of the G-protein / 33 subgene gene and is used together with the first nucleic acid / or the second nucleic acid.
- a nucleic acid set comprising: a third nucleic acid capable of specifically amplifying a partial DNA region containing the base at position 825 of the 83subunit gene;
- the first labeling substance which specifically hybridizes to a partial region containing a base corresponding to the base at position -482 in the antisense strand of the apolipoprotein C-III gene in which the base at position -482 is C Specific to the first nucleic acid labeled with, and the partial region containing the base corresponding to the -482 base in the antisense strand of the C-II gene, where the -482 base is T
- a nucleic acid set consisting of: a third nucleic acid that can be used together with the nucleic acid to specifically amplify a partial DNA region containing the ⁇ 482 base of the apolipoprotein C-III gene; and (6) -6 An position whose base is G Otenshino in the sense strand of one plasminogen gene - 6 A first nucleic acid specifically hybridized to a partial region containing a base, and labeled with a first labeling substance; and at position -6 in the sense strand of the angiotensinogen gene having base A at position -6.
- two or more nucleic acid sets are selected from the group consisting of (1) to (6) to form a kit.
- a kit may be formed by selecting two or more nucleic acid sets from such a group. For example, from the group consisting of (1) to (5) (a set of nucleic acids for analyzing the top 5 polymorphisms selected in consideration of the odds ratio and P value in the examples described later)
- a kit can be constructed by selecting two or more nucleic acid sets, or a group consisting of (1), (3), (4), and (5).
- a nucleic acid set for analyzing polymorphisms up to the order can be used to construct a kit by selecting two or more nucleic acid sets.
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (7) to ( ⁇ ):
- the antisense strand of the thrombosbondin 4 gene in which the base at position 186 is G specifically hybridizes to the partial region containing the base corresponding to base at position 186, and Specific hybridization to the first nucleic acid labeled with the labeling substance and the partial region containing the base corresponding to the base position 86 in the antisense strand of the thrombosbondin 4 gene in which the base position 186 is C And labeled with a second labeling substance And the second nucleic acid and the thrombospondin 4 gene specifically hybridized to a partial region of the sense strand of the tombo spondin 4 gene and used together with the first nucleic acid or the second nucleic acid.
- a third nucleic acid capable of specifically amplifying a partial DNA region containing the base at position 1186, and a nucleic acid set comprising:
- a partial region containing a base at position ⁇ 863 specifically hybridizes to and is labeled with the first labeling substance.
- the nucleic acid and a partial region containing the ⁇ 863 base in the sense strand of the tumor necrosis factor a gene in which the ⁇ 863 base is ⁇ are specifically hybridized to and labeled with a second labeling substance.
- a third nucleic acid capable of specifically amplifying a partial DNA region containing bases, and a nucleic acid set comprising:
- the nucleic acid and the partial region containing the base at position 5713 in the antisense gene of the tokubo npopoietin gene whose base at position 5713 is G are specifically high.
- a second nucleic acid which has been pre-hybridized and labeled with a second labeling substance, and together with the first nucleic acid and / or the second nucleic acid specifically hybridized to a partial region of the sense strand of the tobacco mouthbopoietin gene
- a third nucleic acid that can be used to specifically amplify a partial DNA region containing the 57-3 base of the tronpopoietin gene, and a nucleic acid set comprising:
- a first labeling substance that specifically hybridizes to a partial region containing a base corresponding to the 994th base in the antisense strand of the platelet activating factor acetylhydrolase gene in which the 994th base is G, and Specifically hybridized to the first nucleic acid labeled with, and the partial region containing the base corresponding to base 994 in the antisense strand of the platelet-activating factor acetylhydrolase gene having base T at position 994
- a second nucleic acid labeled with a second labeling substance and specifically hybridizes to a partial region of a sense strand of a platelet activating factor acetyl hydrolase gene, and the first nucleic acid or the second nucleic acid
- a kit is configured by selecting two or more nucleic acid sets from the group consisting of (7) to (11), but two or more of (7) to (11) are optional.
- a kit may be formed by selecting two or more nucleic acid sets from such a group.
- a nucleic acid set consisting of (7) to (10) (a nucleic acid set for analyzing polymorphisms with the highest odds ratio of 4 in the examples described below) and a nucleic acid set of two or more lines
- a kit can be constructed by selecting two or more nucleic acid sets. Including two or more nucleic acid sets selected from the group consisting of the following (12) to (17) Genotype detection kit,
- the nucleic acid and a partial region containing a base corresponding to the base at position 561 in the sense strand of the E-selectin gene in which the base at position 561 is C were specifically hybridized to and labeled with a second labeling substance.
- the second nucleic acid and the first nucleic acid or the second nucleic acid specifically hybridizing to a partial region of the antisense strand of the E-selectin gene; and
- a third nucleic acid capable of specifically amplifying a partial DNA region containing base 561 of the selectin gene, and a nucleic acid set comprising:
- the antisense strand of the fatty acid binding protein 2 gene in which the base at position 2445 is G specifically hybridizes to the partial region containing the base at position 2445 and is labeled with the first labeling substance.
- the second nucleic acid specifically hybridized to the nucleic acid and the partial region containing the 2445th base in the antisense strand of the fatty acid binding protein 1 gene in which the 2445th base is A and labeled with a second labeling substance
- a nucleic acid set comprising: a third nucleic acid capable of specifically amplifying a partial DNA region containing
- a specific region containing a base corresponding to the base at position 1018 is specifically hybridized with the first region and the first region. Specifically hybridizes to the first nucleic acid labeled with a labeling substance and to a partial region containing a base corresponding to the 1018 base in the antisense strand of the daricoprotein Ibex gene having a T at the 1018 base. And a second nucleic acid labeled with a second labeling substance and a partial region of the sense strand of glyco'protein Iba gene. To specifically amplify and partially amplify the partial DNA region containing the base position 108 of the Dalicoprotein I ba gene when used in conjunction with the first nucleic acid and / or the second nucleic acid.
- a set of nucleic acids designed to specifically amplify a partial DNA region containing a polymorphic portion at position -668 of the plasminogen activator inhibitor 1 gene
- the plasminogen activator inhibitor 1 gene in which four Gs are continuously present in the 3 ′ direction from the position -668, to the ⁇ -type and the nucleic acid amplified using the set of nucleic acids
- a third nucleic acid that specifically and specifically hybridizes, and a plasminogen activator inhibitor-1 gene having five consecutive G's in the 3'-direction from position -668, wherein the gene is ⁇ -type and said set of nucleic acids
- a fourth nucleic acid specifically hybridizing to a nucleic acid to be amplified by using a nucleic acid set comprising:
- a partial region containing the base corresponding to the base at position 584 is specifically hybridized to and labeled with the first labeling substance.
- a specific region comprising a base region corresponding to base 584 in the antisense strand of the para-xenonase gene having base A at position 584, and the second nucleic acid
- a second nucleic acid labeled with a labeling substance and specifically hybridizing to a partial region of the sense strand of the para-xonase gene and used together with the first nucleic acid and / or the second nucleic acid.
- a third nucleic acid capable of specifically amplifying a partial DMA region containing base 584 of the paraoxonase gene; and a nucleic acid set comprising:
- a nucleic acid set comprising: a third nucleic acid capable of specifically amplifying a partial DNA region containing the base at position 3932.
- two or more nucleic acid sets are selected from the group consisting of (12) to (17) to form a kit.
- the kit may be arbitrarily selected to form a group, and two or more nucleic acid sets may be selected from the group to constitute a kit.
- two or more nucleic acid sets are selected from the group consisting of (12) to (6) (a nucleic acid set for analyzing polymorphisms having the top five odds ratios in the examples described later).
- a kit consisting of (1 2) to (15) (a nucleic acid set for analyzing polymorphisms with the top four in terms of the heads ratio in the examples described later) is composed of two groups.
- a kit can be constructed by selecting one or more nucleic acid sets.
- a genotype detection kit comprising two or more nucleic acid sets selected from the group consisting of the following (18) to (22):
- a set of nucleic acids (first nucleic acid and second nucleic acid) designed to specifically amplify a partial DNA region containing a polymorphic portion at position -668 of the plasminogen activator inhibitor 1 gene
- the plasminogen activator inhibitor gene which has four consecutive G's in the 3'-direction from position -668, is type I and specific for nucleic acids amplified using the set of nucleic acids
- a third nucleic acid, which specifically hybridizes, and a plasminogen activator inhibitor-1 gene having five consecutive G's in the 3 'direction from position -668, wherein the A fourth nucleic acid specifically hybridizing to a nucleic acid to be amplified using a nucleic acid set comprising:
- a partial region containing a base corresponding to the base at position 482 is specifically hybridized.
- a nucleic acid set comprising: a nucleic acid or a third nucleic acid that can be used together with the second nucleic acid to specifically amplify a partial DNA region containing the ⁇ 482 base of the apolipoprotein C-III gene;
- a partial region containing a base corresponding to the base at position 584 is specifically hybridized and labeled with the first labeling substance. Specifically hybridized to the first nucleic acid and a partial region containing the base corresponding to the 584th base in the antisense strand of the paraoxonase gene having the A at the 584th base and being labeled with the second labeling substance.
- a nucleic acid set comprising: a third nucleic acid capable of specifically amplifying a partial DMA region containing the base at position 584;
- the first labeling substance that specifically hybridizes to a partial region containing a base corresponding to the 1018 base in the antisense strand of the glycoprotein I ba gene having a C at the 1018 base, and And a partial region containing a base corresponding to the base at position 1018 in the antisense strand of the dalicoprotein I ba gene having base T at position 1018, and Specifically hybridizes to a second nucleic acid labeled with the labeling substance of No. 2 and to a partial region of the sense strand of the Daricoprotein Ibo; gene, and is used together with the first nucleic acid and / or the second nucleic acid.
- a third nucleic acid capable of specifically amplifying a partial DNA region containing the base at position 1018 of the dalicoprotein I ba gene and a nucleic acid set comprising: (22) A specific region that hybridizes specifically to a partial region containing a base corresponding to base 3932 in the antisense strand of the apolipoprotein gene in which base 3939 is T, and Specifically hybridizes to a first nucleic acid labeled with a labeling substance and a partial region containing a base corresponding to base 3932 in the antisense strand of the apolipoprotein ⁇ gene having base C at position 3932, and A second nucleic acid labeled with the labeling substance of 2, and specifically hybridizing to a partial region of the sense strand of the apolipoprotein ⁇ gene, and used together with the first nucleic acid and / or the second nucleic acid.
- kits are configured by selecting two or more nucleic acid sets from the group consisting of (18) to (22), but two or more of (18) to (22) are arbitrarily selected.
- a kit may be formed by selecting two or more nucleic acid sets from such a group. For example, two or more nucleic acid sets are selected from a group consisting of (18) to (21) (a nucleic acid set for analyzing polymorphisms having the highest four odds ratios in the examples described later) and a kit is selected. Or a group consisting of (18) to (20) (a nucleic acid set for analyzing polymorphisms with the top three ranked in the examples described later).
- a kit can be configured by selecting a tool. In the above kit, one or more reagents (buffers, reaction reagents, detection reagents, etc.) according to the method of using the kit may be combined.
- polymorphisms present in these genes those located in the promoter region ⁇ exon, or those located in the splice donor site and the ⁇ ceptor site and expected to be associated with a change in the function of the gene product, mainly We selected 112 polymorphisms (Figs. 1 and 2).
- the subjects were 1869 Japanese patients (1313 males and 556 females) who were hospitalized for coronary angioplasty (balloon dilatation or stent insertion) between July 1998 and December 2001.
- Follow-up coronary angiography was performed 6 months after coronary angioplasty. Coronary artery stenosis lesions that resulted in acute occlusion or subacute intrastent thrombosis after balloon dilatation were excluded from the analysis.
- vascular stenosis was defined as a minimum vascular stenosis of 50% or more at the site of coronary angioplasty.
- 7 mL of venous blood was collected into a tube containing 50 mol / L EDTA-2Na, and genomic DNA was extracted using a DMA extraction kit (Qiagen, Chatsworth, CA).
- the genotype of the monobasic polymorphism was determined by a firefly-luminescent, allyl-specific primer-probe measurement system (Toyobo Gene Analysis, Tsuruga, Japan) (see Figures 3 and 4).
- the DNA fragment containing the polymorphic site is labeled at the 5 'end with a flueoresceinisothocyanate (FITC) or Texas red (Texas red: TxR) and is labeled with two different aryl-specific senses.
- FITC flueoresceinisothocyanate
- TxR Texas red
- a DMA fragment containing a polymorphic site can be prepared using two different aryl-specific sense (or antisense) primers and an antisense (or sense) primer labeled with a biotin at the 5 'end, or a sense primer.
- the reaction solution (25 mL) contains 20 ng of DNA, 5 pmol of each primer, 0.2 mmol / L of each dextrin nucleoside triphosphate, 4 mol / L of magnesium chloride, and 1 U of DNA polymerase (rTaq or KODplus). Toyobo, Osaka, Japan), and the respective DMA polymerase buffers were used.
- the amplification protocol had an initial denaturation of 5 min at 95 ° C, 35-45 cycles of denaturation at 95 ° C for 30 seconds, annealing at 55-67, 5 ° C for 30 seconds, and extension at 72 ° C.
- the amplified DNA was incubated at room temperature in a solution containing streptavidin-bound magnetic beads in each well of a 96-well plate. Place this plate on a magnetic stand, collect the supernatant from each well, transfer it to each well of a 96-well plate containing 0.01M NaOH, and excite FITC using a microplate reader. The wavelengths were measured at 485 nm and 538 nm, and TxR measured fluorescence at excitation and fluorescence wavelengths of 584 nm and 612 nm.
- amplified DNA was denatured with 0.3 M NaOH and contained either an aryl-specific capture probe immobilized on the bottom of each well of a 96-well plate and 35-40% formamide.
- Hybridization was performed at 7 ° C for 30 minutes. After the wells were thoroughly washed, alkaline phosphatase-conjugated streptavidin was added to each well, and the plate was shaken at 37 ° C for 15 minutes. Wash the wells again, and 0.8 ⁇ ⁇ 2- (4-iodophenyl) -3- (4-nitropheny I) -5- (2,4-di su I f op eny l) -2H-tet razo I i A solution containing um (monosod i um sal t) and 0. machine 5-bromo-4-ch I oro-3- i ndo I y I phosphate p-to I uidi ne sa It! ] Thereafter, the absorbance at 450 nm was measured.
- genotype determined by the aryl-specific primer-probe measurement system was the same as that determined by the PCR-restriction fragment length polymorphism method or the DNA sequencing method.
- the statistical analysis in the following related analysis was performed as follows. Clinical data were compared between restenotic and non-restenotic lesions using the unpai red Student's test or the Mann-Whitney U test. Qualitative data was tested using the chute square test. The aryl frequency was estimated by the gene counting method, and the deviation from the Hardy-Weynberg equilibrium was tested by the chi-square test.
- Example 3 Selection of polymorphisms related to restenosis after coronary angioplasty, and development of a method for diagnosing restenosis after coronary angioplasty
- the present inventors performed a stepwise forward selection met hod for multinomial logistic regression analysis (FIGS. 10 and 11).
- FGS. 10 and 11 The present inventors performed a stepwise forward selection met hod for multinomial logistic regression analysis (FIGS. 10 and 11).
- dominant or recessive genetic models were used based on the P-value (lower P-value) associated with post-coronary restenosis for each of the polymorphisms shown in Figures 8 and 9.
- the loci on the chromosome of these genes are shown in IH10 and FIG. Although the loci of the tumor necrosis factor ⁇ gene and the platelet activating factor acetylhydrolase gene are close to each other, no association was found in the genotype distribution of the polymorphisms in both subjects.
- Step-wise forward selection The head-to-head ratio of restenosis after balloon dilatation or stent insertion based on the combination genotype calculated by m ethod, for males, Fig. 12, Fig. 13 and Fig. 16 A, and for females, Fig. 14 and Fig. 15 and Fig. 16B.
- a combination genotype of six polymorphisms including one polymorphism (AGT (-6G ⁇ A) polymorphism), resulted in a 15.09-year maximum ratio of restenosis after balloon dilatation (Fig. 16A).
- AGT -6G ⁇ A polymorphism
- Fig. 16A the combined polymorphism of 5 polymorphisms
- TNF ⁇ 863C ⁇ A polymorphism
- TM (2136C ⁇ T) polymorphism
- TP0 5713A ⁇ G
- PAF-AH (994G ⁇ T) polymorphism resulted in a maximum odds ratio of in-stent restenosis of 6.64 (Figs. 13 and 16A).
- multinomial logistic regression analysis revealed that 6 single nucleotide polymorphisms were associated with restenosis after balloon dilatation and 5 single nucleotide polymorphisms were associated with intrastent restenosis in both sexes.
- the present inventors performed a large-scale association analysis of 2391 coronary artery lesions on the relationship between 19 single nucleotide polymorphisms in males and 18 females and restenosis after coronary angioplasty.
- the stepwise forward selection method of the multinomial logistic regression analysis showed that the maximum age ratio was 15.09 for male restenosis after balloon dilatation, 6.64 for intrastent restenosis, and 44.54 for female restenosis after balloon dilation.
- intra-stent restenosis we developed a genetic risk diagnosis method for restenosis after coronary angioplasty using a combination genotype exhibiting 117.83.
- the major cause of balloon dilatation restenosis is chronic remodeling of the coronary arteries, and the major cause of intrastent restenosis is neointimal hyperplasia (Mintz GS, Popma JJ, Pichard AD, et a Arterial remodeling).
- G-protein vascular biology
- E-selectin vascular inflammation
- hypertension angiotensinogen
- lipid metabolism a polypoptin
- E plays a role in apolipoprotein C-III, fatty acid binding protein 2, and para-xonase), platelet function (glycoprotein la and glycoprotein I bo, fibrinolytic system (plasminogen activator inhibitor 1), etc.
- genes related to in-stent restenosis are vascular biology (thrombosbondin 4), vascular inflammation (tumor necrosis factor ⁇ and platelet-activating factor acetyl hydrolase), and lipid metabolism (apolipoprotein ⁇ ). , Apolipoprotein C-III and para-xonase), platelet function (troponpo) Julin, thrombopoietin, glycoprotein lbQ!), Fibrinolytic system (plasminogen activator inhibitor 1), etc.
- One polymorphism in males (tumor necrosis factor ⁇ gene) ) are associated with both restenosis after balloon dilatation and in-stent restenosis.
- apolipoprotein E van Bockxmeer FM, Mamotte CDS, Gibbons FR, Taylor RR. Apo I i poprote in ⁇ 4 homozygos i ty-a determinant of restenos is af ter coronary angioplasty.
- Angiotensinogen Volzke H, Hertwig S, Re 11igR, Motz W.
- the angiotensinogen gene) 235T variant is assoc ia ted wi th an i ncreased risk of restenosis af ter percutaneous trans luminal coronary angioplasty.CI in Sci 2000; 99: 19-25.), plasminogen activity inhibitor 1 (Ort lepp) R , Hoffmann R, Ki IIian A, Lauscher J, Merkel bach-Brese S, Han rath P.
- Atheroscl eros is 2001; 156: 463-468)) and G-protein ⁇ 3 subunit (von Beckerath N, Kastrat i A, Koch W, et a I. G protein ⁇ 3 subun it polymorphism and risk of thrombo sis and restenos is fol lowing coronary stent placement. Atherosclerosis 2000; 149: 151-155.) The gene is thought to be important in the mechanism of restenosis (Matsuno H, Kozawa 0, Niwa M, Uematsu T.
- tumor necrosis factor a (Clausel lN, de Lima VC, Mo I oss i S, et a I.Expression of tumor necros is factor and accumulation of fibronectin in coronary artery rest enot ic lesions retrieved by atherectomy.Br Heart J 1995; 73: 534-9.) and glycoprotein Ib (Gawaz M, Neumann FJ, Ott I, May A, Rudger S, Schoini g A. Changes in membrane glycoproteins of ci. Heart 1996; 76: 166-72.) may play an important role in the pathology of restenosis.
- a genotype associated with restenosis after coronary angioplasty is analyzed, and a genotype of a nucleic acid sample is detected.
- the present invention is an effective means to know in advance the risk of restenosis after performing a specific coronary angioplasty. Therefore, the present invention provides useful information for selecting an optimal treatment method, enables selection of an appropriate treatment method, realizes a high therapeutic effect, and improves the quality of life of patients with coronary artery disease. Can be achieved.
- the present invention provides useful information for elucidating the mechanism by which restenosis occurs, and is therefore a very important means for establishing a method for preventing restenosis.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/524,021 US7645572B2 (en) | 2002-08-09 | 2003-03-20 | Method of diagnosing risk of restenosis after coronary angioplasty |
EP03712818A EP1536001A4 (en) | 2002-08-09 | 2003-03-20 | METHOD FOR DIAGNOSIS OF RESTENOSIS AFTER CORONARANGIOPLASTY |
AU2003221197A AU2003221197A1 (en) | 2002-08-09 | 2003-03-20 | Method of diagnosing risk of restenosis after coronary angioplasty |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002233041A JP4129908B2 (ja) | 2002-08-09 | 2002-08-09 | 冠動脈形成術後再狭窄のリスク診断方法 |
JP2002/233041 | 2002-08-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004015104A1 true WO2004015104A1 (ja) | 2004-02-19 |
Family
ID=31711852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/003478 WO2004015104A1 (ja) | 2002-08-09 | 2003-03-20 | 冠動脈形成術後再狭窄のリスク診断方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7645572B2 (ja) |
EP (1) | EP1536001A4 (ja) |
JP (1) | JP4129908B2 (ja) |
AU (1) | AU2003221197A1 (ja) |
WO (1) | WO2004015104A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4140329B2 (ja) | 2002-09-25 | 2008-08-27 | 財団法人名古屋産業科学研究所 | 高血圧のリスク診断方法 |
WO2005087953A2 (en) * | 2004-03-05 | 2005-09-22 | Applera Corporation | Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof |
JP5033392B2 (ja) * | 2006-03-10 | 2012-09-26 | 国立大学法人三重大学 | 2型糖尿病の遺伝的リスク検出法 |
GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
US7550300B1 (en) * | 2007-11-29 | 2009-06-23 | Capgen Sciences, Inc. | Prediction of bare metal stent restenosis |
ES2344396B1 (es) * | 2009-02-24 | 2011-06-24 | Fina Biotech Slu | Marcadores geneticos del riesgo de sufrir reestenosis. |
RU2532340C2 (ru) * | 2012-12-18 | 2014-11-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Способ прогнозирования вероятности развития рестеноза после стентирования коронарных артерий |
RU2523391C1 (ru) * | 2013-03-06 | 2014-07-20 | Галина Александровна Чумакова | Способ прогнозирования риска развития рестеноза коронарных артерий после их стентирования у пациентов с ишемической болезнью сердца |
RU2662413C1 (ru) * | 2017-09-27 | 2018-07-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования рестеноза стентов при чрескожном коронарном вмешательстве у больных ишемической болезнью сердца |
RU2662366C1 (ru) * | 2017-11-07 | 2018-07-25 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования тромбоза в коронарном стенте при чрескожном коронарном вмешательстве у больных ишемической болезнью сердца |
RU2690892C1 (ru) * | 2018-12-26 | 2019-06-06 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО "ПИМУ" Минздрава России) | Способ прогнозирования тромбоза стента у больных острым коронарным синдромом после чрескожного коронарного вмешательства на фоне двойной антитромбоцитарной терапии |
RU2748010C1 (ru) * | 2020-05-07 | 2021-05-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития рестеноза коронарной артерии после стентирования голометаллическим или стентом с лекарственным покрытием у больных ишемической болезнью сердца |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
-
2002
- 2002-08-09 JP JP2002233041A patent/JP4129908B2/ja not_active Expired - Fee Related
-
2003
- 2003-03-20 AU AU2003221197A patent/AU2003221197A1/en not_active Abandoned
- 2003-03-20 US US10/524,021 patent/US7645572B2/en not_active Expired - Fee Related
- 2003-03-20 WO PCT/JP2003/003478 patent/WO2004015104A1/ja not_active Application Discontinuation
- 2003-03-20 EP EP03712818A patent/EP1536001A4/en not_active Withdrawn
Non-Patent Citations (7)
Title |
---|
BAUTERS C. ET AL.: "Gene polymorphisms and outcome after coronary angioplasty", CURR. INTERV. CARDIOL. REP., vol. 3, no. 4, November 2001 (2001-11-01), pages 281 - 286, XP002969327 * |
HAMON M. ET AL.: "Dual determination of angiotensin-converting enzyme and angiotensin-II type 1 receptor genotypes as predictors of restenosis after coronary angioplasty", AM. J. CARDIOL., vol. 81, no. 1, January 1998 (1998-01-01), pages 79 - 81, XP002969329 * |
RIBICHINI F.: "In-stent restenosis", ITAL. HEART J., vol. 2, no. 10, October 2001 (2001-10-01), pages 728 - 735, XP002969326 * |
See also references of EP1536001A4 * |
TANIGUCHI I. ET AL.: "The DD genotype of angiotensin converting enzyme polymorphism is a risk factor for coronary artery disease and coronary stent restenosis in Japanese patients", JPN. CIRC. J., vol. 65, no. 10, October 2001 (2001-10-01), pages 897 - 900, XP002969328 * |
VON BECKERATH N. ET AL.: "Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting", BLOOD, vol. 95, no. 11, June 2000 (2000-06-01), pages 3297 - 3301, XP002969325 * |
ZEE R.Y. ET AL.: "Multi-locus interactions predict risk for post-PTCA restenosis: an approach to the genetic analysis of common complex disease", PHARMACOGENOMICS J., vol. 2, no. 3, June 2002 (2002-06-01), pages 197 - 201, XP002969324 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003221197A8 (en) | 2004-02-25 |
US20060099590A1 (en) | 2006-05-11 |
EP1536001A4 (en) | 2007-02-21 |
JP4129908B2 (ja) | 2008-08-06 |
AU2003221197A1 (en) | 2004-02-25 |
JP2004065203A (ja) | 2004-03-04 |
EP1536001A1 (en) | 2005-06-01 |
US7645572B2 (en) | 2010-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7745137B2 (en) | Method of diagnosing risk of myocardial infarction by detection of specific gene polymorphisms | |
KR102158717B1 (ko) | Cd163l1 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
US20230036585A1 (en) | Novel methods for early identification of bone healing ability in injured patients | |
KR101546058B1 (ko) | 대사증후군 예측용 snp 마커 및 이의 용도 | |
WO2004015104A1 (ja) | 冠動脈形成術後再狭窄のリスク診断方法 | |
Horibe et al. | Genetic risk for restenosis after coronary balloon angioplasty | |
Rudež et al. | Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions | |
JP4140329B2 (ja) | 高血圧のリスク診断方法 | |
KR102158715B1 (ko) | Olfml2a 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158721B1 (ko) | Rnf144a 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158713B1 (ko) | Gba 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
JP4385140B2 (ja) | 心筋梗塞のリスク検査方法 | |
JP2010515467A (ja) | 心筋梗塞及び心不全における診断マーカー及び薬剤設計のためのプラットホーム | |
KR102158724B1 (ko) | Lingo2 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158718B1 (ko) | Cul4a 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158716B1 (ko) | Arhgap32 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158723B1 (ko) | Spcs3 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158719B1 (ko) | Loc102724084 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158725B1 (ko) | Mink1 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158720B1 (ko) | Lrrc3 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158714B1 (ko) | Tcf24 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
KR102158722B1 (ko) | Flj45964 유전자의 단일염기다형성을 포함하는 뇌동맥류 진단용 snp 마커 | |
US7888020B2 (en) | Association of EDG5 polymorphism V286A with type II diabetes mellitus and venous thrombosis/pulmonary embolism and the use thereof | |
JP4129910B2 (ja) | 冠動脈攣縮のリスク診断方法 | |
KR20230150127A (ko) | 심근경색과 연관된 유전자 다형성 및 그의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006099590 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10524021 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003712818 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003712818 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10524021 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003712818 Country of ref document: EP |